Intellia Therapeutics Inc. (NASDAQ: NTLA) reported longer-term Phase 1 data for its investigational treatment nexiguran ziclumeran in patients with transthyretin ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE